Skip to main content

Table 2 Clinical characteristics and its association with LTFU

From: Predictors of the observed high prevalence of loss to follow-up in ART-experienced adult PLHIV: a retrospective longitudinal cohort study in the Tanga Region, Tanzania

Sample characteristic

LTFU

p-value

No (%)

Yes (%)

Total

Viral load suppression

    

 Not suppressed

2602 (68.22)

1212 (31.78)

3814 (24.92)

 < 0.0001

 Suppressed

9777 (85.10)

1712 (14.90)

11,489 (75.08)

BMI (kg/m2)

    

 < 18.5

86 (30.82)

193 (69.18)

279 (0.49)

 < 0.0001

 18.5–< 30

41,624 (74.05)

14,585 (25.95)

56,209 (98.31)

 25–< 30

62 (30.85)

139 (69.15)

201 (0.35)

 30 + 

290 (59.92)

194 (40.08)

484 (0.85)

WHO

    

 I

8294 (69.28)

3678 (30.72)

11,972 (26.82)

 < 0.0001

 II

5370 (73.57)

1929 (26.43)

7299 (16.35)

 III

15,544 (75.65)

5004 (24.35)

20,548 (46.04)

 IV

3460 (71.90)

1352 (28.10)

4812 (10.78)

Drug type

    

 First-line

40,981 (74.21)

14,240 (25.79)

55,221 (97.89)

0.3707

 Second-line

868 (73.06)

320 (26.94)

1188 (2.11)

ART duration

    

 ≤ 1

10,488 (79.10)

2771 (20.90)

13,259 (23.19)

 < 0.0001

 > 1

31,574 (55.23)

12,340 (21.58)

43,914 (76.81)

Adherence

    

 Good

40,000 (75.86)

12,731 (24.14)

52,731 (97.03)

 < 0.0001

 Poor

721 (44.62)

895 (55.38)

1616 (2.97)

DTG-based regimen

    

 No

2087 (16.17)

10,819 (83.83))

12,906 (22.57)

 < 0.0001

 Yes

39,975 (90.30)

4292 (9.70)

44,267 (77.43)

TB history

    

 No

42,015 (73.73)

14,971 (26.27)

56,986 (99.67)

 < 0.0001

 Yes

47 (25.13)

140 (74.87)

187 (0.33)

 
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us